![Phosphate disorders and the clinical management of hypophosphatemia and hyperphosphatemia | Endocrinología, Diabetes y Nutrición (English ed.) Phosphate disorders and the clinical management of hypophosphatemia and hyperphosphatemia | Endocrinología, Diabetes y Nutrición (English ed.)](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S2530018020300330:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w997EogCnBdOOD93cPFbanNf23BlP/DWEpPOpuWlfofnyqxn4xVHcGY2cyFujnbUAmMXNwxGCrVrd+DktCrPY3vx4P9qoqDtrfSGaqlR4iTxWxkwCTdYeanvcGy/iY6gsy8lMyN2l3GLUkog83JvGJddDwgGrAbJeGBbPYJPWFjJDug/KBdaA/ff9jcNRcDQVOLBRk8W15bqq5S9ISFQY1z9g95j+CNqOyF6xU0sx6eK8qqw+AQ76T8xYuZVsOylhfu58s9RMju1yiABJnH1TZSIWC1rpBC8IJGtYu4S0nyXn)
Phosphate disorders and the clinical management of hypophosphatemia and hyperphosphatemia | Endocrinología, Diabetes y Nutrición (English ed.)
![SEPEAP on Twitter: "Metabolismo fosfocálcico #pediatriaintegral https://t.co/3SfyQ6LRO1 https://t.co/qQszih43ev" / Twitter SEPEAP on Twitter: "Metabolismo fosfocálcico #pediatriaintegral https://t.co/3SfyQ6LRO1 https://t.co/qQszih43ev" / Twitter](https://pbs.twimg.com/media/EsAfrDDXUAIlp15.png)
SEPEAP on Twitter: "Metabolismo fosfocálcico #pediatriaintegral https://t.co/3SfyQ6LRO1 https://t.co/qQszih43ev" / Twitter
![Metabolismo mineral óseo en pacientes con enfermedad renal crónica: Revisión sobre su fisiopatología y morbimortalidad Metabolismo mineral óseo en pacientes con enfermedad renal crónica: Revisión sobre su fisiopatología y morbimortalidad](http://www.scielo.org.pe/img/revistas/rins/v32n2/a18fig01.jpg)
Metabolismo mineral óseo en pacientes con enfermedad renal crónica: Revisión sobre su fisiopatología y morbimortalidad
![Nose-to-brain lipid nanocarriers: An active transportation across BBB in migraine management - ScienceDirect Nose-to-brain lipid nanocarriers: An active transportation across BBB in migraine management - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0009308422000056-ga1.jpg)
Nose-to-brain lipid nanocarriers: An active transportation across BBB in migraine management - ScienceDirect
![Alteraciones del Metabolismo Mineral: Calcio, Fósforo, PTH, Vitamina D, FGF-23, Klotho | Nefrología al día Alteraciones del Metabolismo Mineral: Calcio, Fósforo, PTH, Vitamina D, FGF-23, Klotho | Nefrología al día](https://static.elsevier.es/nefro/monografias/1/311/1853.jpg)
Alteraciones del Metabolismo Mineral: Calcio, Fósforo, PTH, Vitamina D, FGF-23, Klotho | Nefrología al día
![PDF] Le alterazioni del metabolismo calcio-fosforo nei pazienti in dialisi: il contributo dello Studio DOPPS. Il punto di vista infermieristico by Marisa Pegoraro · OA.mg · 10.5301/gtnd.2012.9980 PDF] Le alterazioni del metabolismo calcio-fosforo nei pazienti in dialisi: il contributo dello Studio DOPPS. Il punto di vista infermieristico by Marisa Pegoraro · OA.mg · 10.5301/gtnd.2012.9980](https://og.oa.mg/Le%20alterazioni%20del%20metabolismo%20calcio-fosforo%20nei%20pazienti%20in%20dialisi:%20il%20contributo%20dello%20Studio%20DOPPS.%20Il%20punto%20di%20vista%20infermieristico.png?author=%20Marisa%20Pegoraro)
PDF] Le alterazioni del metabolismo calcio-fosforo nei pazienti in dialisi: il contributo dello Studio DOPPS. Il punto di vista infermieristico by Marisa Pegoraro · OA.mg · 10.5301/gtnd.2012.9980
![Alterazioni del metabolismo del fosforo | CKD-MBD: patologia minerale e ossea secondaria a malattia renale cronica Alterazioni del metabolismo del fosforo | CKD-MBD: patologia minerale e ossea secondaria a malattia renale cronica](http://webapp.edukarea.it/demo_medren/mbd/wp-content/uploads/sites/26/2017/04/MBD_FI006.jpg)
Alterazioni del metabolismo del fosforo | CKD-MBD: patologia minerale e ossea secondaria a malattia renale cronica
![Paricalcitol regulatory effect on inflammatory, fibrotic and anticalcificating parameters in renal patient. Far beyond mineral bone disease regulation | Nefrología Paricalcitol regulatory effect on inflammatory, fibrotic and anticalcificating parameters in renal patient. Far beyond mineral bone disease regulation | Nefrología](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S2013251420300432:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w92lL8PRnKGMnsiVXV6EVJ5QRkjJZIKj2umwUyY+cL6K8cyMCoG0zLrx/ORKa7YTjKZZ/7892wCSeqkfByHYuW7jMVCF6hGyNyOTgzNoeiPajzz4iVnA4dGkbJpKxeEram9q3RNN8DHUpc57d+CIutAYc83AKoxE+sZhnKM6wmSOKpcWbmto2f+RFg6feqGlYYY8FtFxbNh6ZoQZlqLj3NBwf+e4h9gThO0reCydcBamAX2YoIxKcoKEY04R1EV/TqvQTR+bgtd2VBpDyKvlpT0LFDNQDq4r9nxwW+APolITF)